English

Redeye: Initiating coverage of Annexin Pharmaceuticals

Report this content

We are initiating coverage of Annexin Pharmaceuticals, a world-leading biotech company within the Annexin A5 field. We see the early, clinical phases as risk-reduced and where they are in a good position to evaluate the full therapeutic potential of ANXV in several cardiovascular diseases.

Read more and download the initial analysis: http://bit.ly/2xFSBh7

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Subscribe